

## CLAIMS

1.- 11 (deleted)

12. (currently amended) Method of treatment of an individual suffering from a disease selected from the group consisting of insulin resistance, hyperpigmentation and/or inflammatory processes in the skin, fungal diseases, overweight and obesity, and microbacterial infections, comprising administering to said individual an effective amount of a composition comprising a derivative of deoxynojirimycin, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier Use according to claim 10, wherein said derivative comprises a large hydrophobic moiety is derived from a compound selected from the group consisting of adamantanemethanol, cholesterol, .beta.-cholesterol, adamantanol and 9-hydroxyphenanthrene.

13. (currently amended) Use the Method of treatment of claim 12 according to claim 9, wherein said derivative further comprises an apolar side chain is derived from a polycyclic alcohol containing three or more rings each sharing two or more carbon atoms with another ring and is capable of inserting in lipid bilayers, and wherein a the spacer comprises comprising an alkoxy polyalkene or polyalkene chain of from 3 to 8 carbon atoms.

14. (deleted).

15. (currently amended) Method of treatment of an individual suffering from insulin resistance, comprising administering administering to said individual an effective amount of a medicament composition comprising N (5-adamantane-1-yl-methoxy-pentyl)deoxynojirimycine deoxynojirimein derivative, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier, which deoxynojirimein derivative or salt is an inhibitor of glucosylceramide synthase.

16. (currently amended) Method of treatment of an individual suffering from a disease selected from the group consisting of hyperpigmentation and/or inflammatory processes in the skin, fungal diseases, overweight and obesity, and microbacterial infections, comprising administering administering to said individual an effective amount of a medicament composition comprising N (5-adamantane-1-yl-methoxy-pentyl)deoxynojirimycine deoxynojirimein derivative, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

17. (new) Method of treatment of an individual suffering from insulin resistance, said method comprising administering to said individual suffering overweight or obesity an effective amount of a composition comprising N (5-adamantane-1-yl-methoxy-pentyl)deoxynojirimycin, or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.